

Circulating tumor DNA to monitor treatment response patients with metastatic melanoma

Oncotarget

6, 42008-42018

DOI: [10.18632/oncotarget.5788](https://doi.org/10.18632/oncotarget.5788)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 44583-44595.	0.8	77
2	Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. <i>Oncotarget</i> , 2016, 7, 48832-48841.	0.8	234
3	Targeted sequencing reveals <i>TP53</i> as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. <i>Oncotarget</i> , 2016, 7, 61575-61586.	0.8	31
4	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. <i>Aging</i> , 2016, 8, 933-944.	1.4	67
5	Curcumin: A new candidate for melanoma therapy?. <i>International Journal of Cancer</i> , 2016, 139, 1683-1695.	2.3	212
6	Clinical significance of <i>BRAF</i> mutation status in circulating tumor DNA of metastatic melanoma patients at baseline. <i>Experimental Dermatology</i> , 2016, 25, 783-788.	1.4	34
7	Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. <i>BMC Cancer</i> , 2016, 16, 850.	1.1	22
8	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5480-5486.	3.2	84
9	New insights in melanoma biomarkers: long-noncoding RNAs. <i>Melanoma Management</i> , 2016, 3, 195-205.	0.1	0
10	Pathologists and liquid biopsies: to be or not to be?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 601-609.	1.4	49
11	Circulating biomarkers to monitor cancer progression and treatment. <i>Computational and Structural Biotechnology Journal</i> , 2016, 14, 211-222.	1.9	118
12	Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?. <i>Clinical Cancer Research</i> , 2016, 22, 3992-3998.	3.2	48
13	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , 2016, 6, 286-299.	7.7	208
14	The feasibility of using mutation detection in ctDNA to assess tumor dynamics. <i>International Journal of Cancer</i> , 2017, 140, 2642-2647.	2.3	82
15	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017, 17, 223-238.	12.8	1,786
16	Droplet-Based Digital PCR. <i>Advances in Clinical Chemistry</i> , 2017, 79, 43-91.	1.8	87
17	Advances in Circulating Tumor DNA Analysis. <i>Advances in Clinical Chemistry</i> , 2017, 80, 73-153.	1.8	23
18	Circulating Tumor DNA as Biomarkers for Cancer Detection. <i>Genomics, Proteomics and Bioinformatics</i> , 2017, 15, 59-72.	3.0	185

#	ARTICLE	IF	CITATIONS
19	Current and Emerging Applications of Droplet Digital PCR in Oncology. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 493-510.	1.6	151
20	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. <i>Annals of Oncology</i> , 2017, 28, 1130-1136.	0.6	253
21	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945
22	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
23	Intratumor and Intertumor Heterogeneity in Melanoma. <i>Translational Oncology</i> , 2017, 10, 956-975.	1.7	217
24	Utilizing circulating tumour DNA in radiation oncology. <i>Radiotherapy and Oncology</i> , 2017, 124, 357-364.	0.3	19
25	Liquid Biopsy: Value for Melanoma Therapy?. <i>Oncology Research and Treatment</i> , 2017, 40, 430-434.	0.8	9
26	Liquid Biopsy in Cancer Patients. <i>Current Clinical Pathology</i> , 2017, , .	0.0	6
27	Liquid Biopsies in Malignant Melanoma: From Bench to Bedside. <i>Current Clinical Pathology</i> , 2017, , 161-193.	0.0	0
28	Clinical value of early detection of circulating tumour DNA-BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor. <i>ESMO Open</i> , 2017, 2, e000173.	2.0	8
29	Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 697-710.	1.2	17
30	Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 86, 349-357.	1.3	82
31	Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations. <i>Pharmaceutical Medicine</i> , 2017, 31, 217-233.	1.0	4
32	Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. <i>BMC Cancer</i> , 2017, 17, 428.	1.1	99
33	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. <i>Cancer Letters</i> , 2017, 404, 62-69.	3.2	98
34	Metastatic pathways in patients with cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 13-27.	1.5	38
35	Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. <i>Oncology Letters</i> , 2017, 15, 1839-1844.	0.8	12
36	Concerning the article by Louveuet al "Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor" <i>ESMO Open</i> , 2017, 2, e000207.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Dual roles of yes-associated protein (YAP) in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 75727-75741.	0.8	50
38	Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients. <i>Annales De Biologie Clinique</i> , 2017, 75, 619-630.	0.2	7
39	Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1212-1218.	0.6	29
40	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	1.3	61
41	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	39
42	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. <i>Oncotarget</i> , 2017, 8, 78174-78192.	0.8	75
43	Detection of tumor-derived DNA dispersed in the airway improves the diagnostic accuracy of bronchoscopy for lung cancer. <i>Oncotarget</i> , 2017, 8, 79404-79413.	0.8	15
44	Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. <i>Oncotarget</i> , 2017, 8, 59268-59281.	0.8	19
45	Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1363-1374.	0.9	59
46	Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. <i>Oncotarget</i> , 2017, 8, 60094-60108.	0.8	85
47	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	51
48	Liquid biopsy to monitor melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 405-414.	0.4	19
49	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , 2018, 64, 830-842.	1.5	50
50	Liquid Biopsy zur Überwachung von Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 405-416.	0.4	6
51	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018, 244, 616-627.	2.1	91
52	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3
53	Emerging Biomarkers in Cutaneous Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 203-218.	1.6	35
54	“Future-Proofing” Blood Processing for Measurement of Circulating miRNAs in Samples from Biobanks and Prospective Clinical Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 208-218.	1.1	28

#	ARTICLE	IF	CITATIONS
55	Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?. <i>Annals of Oncology</i> , 2018, 29, 311-323.	0.6	74
56	Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 240-252.	1.2	32
57	Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. <i>Annals of Oncology</i> , 2018, 29, 490-496.	0.6	124
58	Single Color Multiplexed ddPCR Copy Number Measurements and Single Nucleotide Variant Genotyping. <i>Methods in Molecular Biology</i> , 2018, 1768, 323-333.	0.4	5
59	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	1.4	281
60	Circulating cell-free DNA for non-invasive cancer management. <i>Cancer Genetics</i> , 2018, 228-229, 169-179.	0.2	71
61	Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 119, 42-47.	0.9	31
62	Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1-12.	2.0	40
63	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. <i>Melanoma Research</i> , 2018, 28, 65-70.	0.6	18
64	Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	1.5	25
65	Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease. <i>JCO Precision Oncology</i> , 2018, 2, 1-30.	1.5	13
66	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	13
67	Elevated Levels of BRAF ^{V600} Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-17.	1.5	3
68	Droplet Digital PCR Based Detection of EGFR Mutations in Advanced Lung Cancer Patient Liquid Biopsies: A Comparison of Circulating Tumour DNA Extraction Kits. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2018, 09, .	0.4	3
69	Emerging Concepts in Liquid Biopsy. <i>Advances in Molecular Pathology</i> , 2018, 1, 183-191.	0.2	0
70	Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 83-95.	0.8	10
71	Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9111-9116.	1.0	10
72	Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. <i>Oncotarget</i> , 2018, 9, 36238-36249.	0.8	28

#	ARTICLE	IF	CITATIONS
73	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
74	Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. <i>BMC Medicine</i> , 2018, 16, 166.	2.3	181
75	Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients. <i>Journal of Ovarian Research</i> , 2018, 11, 85.	1.3	21
76	Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	95
77	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. <i>Frontiers in Pharmacology</i> , 2018, 9, 856.	1.6	68
78	Cell-Free DNA in Oncology: Gearing up for Clinic. <i>Annals of Laboratory Medicine</i> , 2018, 38, 1-8.	1.2	45
79	A diagnostic autoantibody signature for primary cutaneous melanoma. <i>Oncotarget</i> , 2018, 9, 30539-30551.	0.8	29
80	Circulating Tumor DNA for Early Cancer Detection. <i>journal of applied laboratory medicine</i> , The, 2018, 3, 300-313.	0.6	25
81	Evaluation of commercial kits for purification of circulating free DNA. <i>Cancer Genetics</i> , 2018, 228-229, 21-27.	0.2	90
82	Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts Survival. <i>Clinical Chemistry</i> , 2018, 64, 1338-1346.	1.5	9
83	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 639-650.	12.5	152
84	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018, 18, 726.	1.1	77
85	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9
86	Liquid biomarkers in melanoma: detection and discovery. <i>Molecular Cancer</i> , 2018, 17, 8.	7.9	74
87	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. <i>Clinical Cancer Research</i> , 2018, 24, 6212-6222.	3.2	168
88	From validity to clinical utility: the influence of circulating tumor <scp>DNA</scp> on melanoma patient management in a real-world setting. <i>Molecular Oncology</i> , 2018, 12, 1661-1672.	2.1	32
89	Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 22.	2.3	30
90	Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). <i>International Journal of Oncology</i> , 2018, 53, 1395-1434.	1.4	41

#	ARTICLE	IF	CITATIONS
91	Characterizing the Cancer Genome in Blood. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a026880.	2.9	7
92	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. Scientific Reports, 2019, 9, 11542.	1.6	25
93	Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report. Clinical Case Reports (discontinued), 2019, 7, 1445-1449.	0.2	3
95	Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. Oncotarget, 2019, 10, 4397-4406.	0.8	27
96	Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing. Molecular Oncology, 2019, 13, 1669-1683.	2.1	8
97	Clinical Use of Cell-Free DNA in Tumor Diagnostics. Advances in Molecular Pathology, 2019, 2, 153-162.	0.2	0
98	Use of circulating tumoral DNA to guide treatment for metastatic melanoma. Pharmacogenomics, 2019, 20, 1259-1270.	0.6	6
99	Liquid biopsy in breast cancer: A comprehensive review. Clinical Genetics, 2019, 95, 643-660.	1.0	210
100	Detection of BRAFV600E Mutation in Melanoma Patients by Digital PCR of Circulating DNA. Genetic Testing and Molecular Biomarkers, 2019, 23, 241-245.	0.3	19
101	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology, 2019, 30, 1448-1459.	0.6	146
102	Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Critical Reviews in Oncology/Hematology, 2019, 141, 36-42.	2.0	49
103	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. American Journal of Clinical Dermatology, 2019, 20, 817-827.	3.3	29
104	Circulating Tumor DNA Analysis and Opportunities for Personalized Cancer Medicine. , 2019, , 229-242.		0
105	Cell-free DNA diagnostics: current and emerging applications in oncology. Pharmacogenomics, 2019, 20, 357-380.	0.6	12
106	Clinical protein science in translational medicine targeting malignant melanoma. Cell Biology and Toxicology, 2019, 35, 293-332.	2.4	33
107	The emerging role of cell-free DNA as a molecular marker for cancer management. Biomolecular Detection and Quantification, 2019, 17, 100087.	7.0	375
108	Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. BMC Cancer, 2019, 19, 192.	1.1	32
109	Resolving genetic heterogeneity in cancer. Nature Reviews Genetics, 2019, 20, 404-416.	7.7	443

#	ARTICLE	IF	CITATIONS
110	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019, 11, 196.	1.7	23
111	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 418-426.	1.2	18
112	Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. <i>PLoS ONE</i> , 2019, 14, e0211866.	1.1	16
113	Toward liquid biopsies in cancer treatment: application of circulating tumor DNA. <i>Apmis</i> , 2019, 127, 329-336.	0.9	16
114	Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 820-828.	1.9	87
116	Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers. <i>Cells</i> , 2019, 8, 1459.	1.8	17
117	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. <i>BMC Cancer</i> , 2019, 19, 1109.	1.1	9
118	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	25
119	Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients. <i>Cancers</i> , 2019, 11, 1938.	1.7	23
120	ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. <i>Scientific Reports</i> , 2019, 9, 17471.	1.6	26
121	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1905.	1.7	14
122	<p>The Role Of Circulating Tumor DNA In Therapeutic Resistance</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9459-9471.	1.0	9
123	Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 5074.	1.3	6
124	The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. <i>Journal of Surgical Research</i> , 2019, 236, 209-215.	0.8	24
125	Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics. <i>Proteomics</i> , 2019, 19, e1700448.	1.3	73
126	Cell-free DNA in cancer: current insights. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 13-28.	2.1	34
127	Monitoring Melanoma Using Circulating Free DNA. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 1-12.	3.3	26
128	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor <sc>DNA</sc> in metastatic melanoma. <i>Molecular Oncology</i> , 2019, 13, 171-184.	2.1	44

#	ARTICLE	IF	CITATIONS
129	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. <i>Acta Dermato-Venereologica</i> , 2019, 99, 206-210.	0.6	22
130	Detection of cell-free circulating <i>BRAF</i> ^V 600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance. <i>British Journal of Dermatology</i> , 2020, 182, 382-389.	1.4	7
131	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 823-834.	1.2	29
132	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
133	Circulating cell-free DNA as a diagnostic and prognostic biomarker for non-small-cell lung cancer: a systematic review and meta-analysis. <i>Biomarkers in Medicine</i> , 2020, 14, 587-597.	0.6	4
134	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. <i>Oncologist</i> , 2020, 25, e520-e527.	1.9	54
135	Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma. <i>Current Opinion in Oncology</i> , 2020, 32, 91-97.	1.1	7
136	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	1.1	11
137	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. <i>Cancers</i> , 2020, 12, 2914.	1.7	26
138	<i>BRAF</i> as a positive predictive biomarker: Focus on lung cancer and melanoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103118.	2.0	17
139	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5926-5933.	3.2	41
140	<p>The Role of Dynamic ctDNA Monitoring During Combination Therapies of <i>BRAF</i> V600E-Mutated Metastatic Colorectal Cancer: A Case Report<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11849-11853.	1.0	3
141	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. <i>Cancers</i> , 2020, 12, 3456.	1.7	12
142	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , 2020, 12, 3486.	1.7	10
143	Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2416-2422.	1.1	17
144	Serial Circulating Tumor DNA Mutational Status in Patients with <i>KRAS</i> -Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. <i>Clinical Chemistry</i> , 2020, 66, 1510-1520.	1.5	11
145	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881.	5.7	253
146	Dynamic ctDNA evaluation of a patient with <i>BRAF</i> V600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis. <i>Acta Oncol&sup3;gica</i> , 2020, 59, 1388-1392.	0.8	0

#	ARTICLE	IF	CITATIONS
147	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. <i>Diagnostics</i> , 2020, 10, 550.	1.3	8
148	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	1.7	22
150	Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 18682.	1.6	40
151	Methylated circulating tumor DNA as a biomarker in cutaneous melanoma. <i>Melanoma Management</i> , 2020, 7, MMT46.	0.1	7
152	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection. <i>Cancers</i> , 2020, 12, 3793.	1.7	12
153	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. <i>Scientific Reports</i> , 2020, 10, 18878.	1.6	16
154	The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review. <i>Therapie</i> , 2020, 75, 183-193.	0.6	0
155	miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma. <i>Neoplasia</i> , 2020, 22, 789-799.	2.3	9
156	Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 999-1013.	2.7	38
157	<p>Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors—Results of a Prospective Biomarker Study</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5017-5032.	1.0	9
158	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 1414.	1.7	15
159	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 111-138.	1.3	27
160	Vorinostat in patients with resistant <i>BRAF^{V600E}</i> mutated advanced melanoma: a proof of concept study. <i>Future Oncology</i> , 2020, 16, 619-629.	1.1	16
161	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 113.	1.6	52
162	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
163	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 20-31.	1.5	19
164	When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 313-321.	3.3	3
165	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. <i>British Journal of Cancer</i> , 2020, 122, 1059-1067.	2.9	41

#	ARTICLE	IF	CITATIONS
166	Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. <i>Tumori</i> , 2020, 106, 241-248.	0.6	13
167	Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives. <i>Current Treatment Options in Oncology</i> , 2020, 21, 19.	1.3	3
168	Biomarkers for Melanoma. , 2020, , 73-104.		0
169	Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma. <i>Journal of Dermatological Science</i> , 2020, 97, 172-178.	1.0	4
170	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of <i>BRAF</i> V600E mutation in plasma from melanoma patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1799-1807.	1.4	10
171	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 1366-1373.	1.1	40
172	Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 517-528.	1.5	60
173	A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6083.	1.6	28
174	Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 960.	1.7	25
175	ctDNA Detection in Microfluidic Platform: A Promising Biomarker for Personalized Cancer Chemotherapy. <i>Journal of Sensors</i> , 2020, 2020, 1-10.	0.6	11
176	Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103187.	2.0	17
177	Prognostic value of absolute quantification of mutated <i>KRAS</i> in circulating tumour DNA in lung adenocarcinoma patients prior to therapy. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 209-219.	1.3	8
178	Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients. <i>Methods in Molecular Biology</i> , 2021, 2265, 247-263.	0.4	0
179	Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management. <i>World Journal of Oncology</i> , 2021, 12, 7-19.	0.6	53
180	PD-L1 Detection on Circulating Melanoma Cells. <i>Methods in Molecular Biology</i> , 2021, 2265, 223-233.	0.4	1
181	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1181-1200.	1.4	68
182	The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 645069.	1.3	18
183	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. <i>Lancet Oncology</i> , The, 2021, 22, 370-380.	5.1	57

#	ARTICLE	IF	CITATIONS
184	BRAF Gene and Melanoma: Back to the Future. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3474.	1.8	40
185	Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis. <i>Cancers</i> , 2021, 13, 1227.	1.7	9
186	Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1041-1049.	0.7	8
187	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
188	Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study. <i>Cancers</i> , 2021, 13, 1826.	1.7	9
189	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. <i>Cancers</i> , 2021, 13, 1740.	1.7	17
190	Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 361-371.	1.6	5
191	Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	0.6	6
192	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. <i>Cancers</i> , 2021, 13, 2616.	1.7	8
193	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. <i>ESMO Open</i> , 2021, 6, 100164.	2.0	69
194	Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing: A Prospective Feasibility Study. <i>Cancers</i> , 2021, 13, 3101.	1.7	5
195	Emodin Suppresses the Migration and Invasion of Melanoma Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 771-779.	0.6	8
196	Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients. <i>Journal of Dermatological Science</i> , 2021, 102, 158-166.	1.0	8
197	Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities. <i>Oncogene</i> , 2021, 40, 5204-5212.	2.6	21
198	The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 671874.	1.3	14
199	Unraveling the Wide Spectrum of Melanoma Biomarkers. <i>Diagnostics</i> , 2021, 11, 1341.	1.3	55
200	Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 725938.	1.3	20
201	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , 2022, 126, 401-408.	2.9	18

#	ARTICLE	IF	CITATIONS
202	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	1.7	5
203	Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?. <i>Meditsinskiy Sovet</i> , 2021, , 48-63.	0.1	2
204	Liquid biopsy: the current state of the issue. <i>Innovative Medicine of Kuban</i> , 2021, , 57-63.	0.0	1
205	Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9714.	1.8	20
206	Extra chromosomal DNA in different cancers: Individual genome with important biological functions. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103477.	2.0	4
207	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
208	A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 123-139.	1.5	155
209	Enrichment and Analysis of ctDNA. <i>Recent Results in Cancer Research</i> , 2020, 215, 181-211.	1.8	13
210	Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219720.	0.2	4
211	Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients. <i>PLoS ONE</i> , 2017, 12, e0188835.	1.1	8
212	PAX3d mRNA over 2.76 copies/ μ L in the bloodstream predicts cutaneous malignant melanoma relapse. <i>Oncotarget</i> , 2017, 8, 85479-85491.	0.8	3
213	Sensitive droplet digital PCR method for detection of <i>TERT</i> promoter mutations in cell free DNA from patients with metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 78890-78900.	0.8	44
214	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018, 9, 32570-32579.	0.8	15
215	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. <i>Oncotarget</i> , 2019, 10, 113-122.	0.8	23
216	Circulating tumor DNA analysis in the era of precision oncology. <i>Oncotarget</i> , 2020, 11, 188-211.	0.8	54
217	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. <i>Oncotarget</i> , 2020, 11, 4016-4027.	0.8	6
218	Issues to Consider in Designing Immunotherapy Clinical Trials for Glioblastoma Management. <i>Journal of Cancer Therapy</i> , 2016, 07, 573-585.	0.1	1
219	BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance). <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 1012-1020.	1.2	4

#	ARTICLE	IF	CITATIONS
220	Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification. <i>British Journal of Pharmacy</i> , 2016, 1, .	0.1	0
221	Circulating Molecular and Cellular Biomarkers in Cancer. , 0, , 607-656.		1
222	Biomarkers for Melanoma. , 2019, , 1-32.		0
223	Novel Methods to Overcome Acquired Resistance to Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 97-129.	0.1	0
224	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
226	NRAS Q61R-mutant mucosal melanoma with cardiac metastasis - a diagnostic challenge. <i>MOJ Clinical & Medical Case Reports</i> , 2020, 10, 146-150.	0.0	0
227	Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 158, 191-207.	1.3	17
228	Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 21, 162-186.	0.9	2
229	A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications. <i>British Journal of Cancer</i> , 2022, 126, 238-246.	2.9	24
230	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. <i>American Journal of Cancer Research</i> , 2018, 8, 1947-1956.	1.4	6
231	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. <i>Cancer Research</i> , 2022, 82, 349-358.	0.4	57
233	Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma. <i>ESMO Open</i> , 2022, 7, 100357.	2.0	10
234	The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. <i>Cancers</i> , 2022, 14, 777.	1.7	3
235	Liquid biopsy in kidney tumor. , 2022, , 101-127.		0
236	Circulating Tumour DNA in Melanoma" Clinic Ready?. <i>Current Oncology Reports</i> , 2022, 24, 363-373.	1.8	10
237	Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 254-262.	0.4	1
238	Future perspectives of uveal melanoma blood based biomarkers. <i>British Journal of Cancer</i> , 2022, 126, 1511-1528.	2.9	22
239	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. <i>BMJ Open</i> , 2022, 12, e055821.	0.8	23

#	ARTICLE	IF	CITATIONS
240	Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives. <i>Current Treatment Options in Oncology</i> , 2022, 23, 562-577.	1.3	8
241	Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy. <i>Cancers</i> , 2021, 13, 6217.	1.7	9
242	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Frontiers in Oncology</i> , 2022, 12, 820510.	1.3	2
243	Cell-Free DNA in Dermatology Research. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1523-1528.e1.	0.3	2
244	BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. <i>BMJ Open</i> , 2022, 12, e060342.	0.8	5
245	Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets. <i>Journal of Personalized Medicine</i> , 2022, 12, 1136.	1.1	6
246	Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
247	Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions. <i>International Immunopharmacology</i> , 2022, 111, 109173.	1.7	3
248	The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma. <i>Cancers</i> , 2022, 14, 4158.	1.7	5
249	Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach. <i>Cancers</i> , 2022, 14, 4153.	1.7	2
251	Role of Electrospun Nanofibers in Cancer Detection and Treatment. , 2022, , 261-275.		0
252	Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor. <i>Acta OncolÃ³gica</i> , 2022, 61, 1263-1267.	0.8	2
253	The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer. <i>Life</i> , 2022, 12, 1640.	1.1	5
254	Current clinically validated applications of liquid biopsy. , 2023, , 63-81.		0
255	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24
256	Circulating Tumour DNA: A Promising Cancer Biomarker. , 2023, , 100-114.		0
257	Liquid biopsy and immunotherapy: is all that glitter gold?. , 2023, , 83-117.		0
258	Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4014.	1.8	5

#	ARTICLE	IF	CITATIONS
260	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 102-138.	0.5	14
261	Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma Research, 2023, 33, 184-191.	0.6	3
262	Synthesis, molecular docking, and biological evaluation of [3,2- <i>b</i>]indole fused 18 β -glycyrrhetic acid derivatives against skin melanoma. RSC Advances, 2023, 13, 11130-11141.	1.7	2
272	Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors. British Journal of Cancer, 2023, 129, 1893-1902.	2.9	3